Trial Profile
A Phase I, Single-Dose, Open-Label, 5-Treatment, Crossover, Pharmacokinetic Study of Comparative Bioavailability of Epinephrine Nasal Spray and EpiPen® in Healthy Adults with Seasonal Allergies
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 15 Mar 2019
Price :
$35
*
At a glance
- Drugs Epinephrine (Primary) ; Epinephrine
- Indications Anaphylaxis
- Focus Pharmacokinetics; Proof of concept
- 25 Feb 2019 Results presented at the 2019 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
- 25 Feb 2019 Results published in the Media Release
- 25 Feb 2019 Status changed from recruiting to active, no longer recruiting, as reported in an INSYS Therapeutics media release.